Janus Henderson Investors US’s Trillium Therapeutics Inc. TRIL Stock Holding History

Janus Henderson Investors US’s Portfolio TRIL Stock Details TRIL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q1	$3.36M	Sell	543,962 -27,241	-5%	-$160K	﹤0.01%	857
2016 Q4	$3.23M	Buy	571,203 +1,619	+0.3%	+$16.1K	﹤0.01%	908
2016 Q3	$8.42M	Buy	569,584 +2,977	+0.5%	+$34.3K	0.01%	729
2016 Q2	$5.09M	Sell	566,607 -34,700	-6%	-$361K	﹤0.01%	779
2016 Q1	$5.56M	Buy	601,307 +48,929	+9%	+$413K	﹤0.01%	760
2015 Q4	$6.96M	Buy	552,378 +49,396	+10%	+$687K	0.01%	770
2015 Q3	$6.55M	Buy	502,982 +128,202	+34%	+$2.36M	0.01%	791
2015 Q2	$8.18M	Buy	+374,780	New	+$8.54M	0.01%	731

Other funds holding TRIL

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

IBT

International Biotechnology Trust London, United Kingdom $297M AUM 17.25% 1-Year Est. Return

SAM

Sectoral Asset Management Montreal, Quebec, Canada $121M AUM 73.47% 1-Year Est. Return

Candriam SCA Strassen, Luxembourg, Luxembourg $19.3B AUM 39.18% 1-Year Est. Return

NLVP

New Leaf Venture Partners New York $43M AUM 25.55% 1-Year Est. Return

Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return

Creative Planning Overland Park, Kansas $147B AUM 18.73% 1-Year Est. Return

PCM

Prelude Capital Management New York $1.31B AUM 62.01% 1-Year Est. Return

Janus Henderson Investors US's TRIL Position: Q1 2017 in Review

Janus Henderson Investors US reduced its Trillium Therapeutics Inc. (TRIL) stake by 4.8% in Q1 2017, selling an estimated $160K and leaving 543,962 shares worth $3.36M. The position accounts for ﹤0.01% of the portfolio, ranked #857.

Janus Henderson Investors US first reported a position in TRIL in Q2 2015 and has held it in 8 quarters since. The position peaked at $8.42M in Q3 2016. 22 funds tracked by Wall St. Rank hold TRIL as of Q1 2017.

Janus Henderson Investors US held 543,962 shares of Trillium Therapeutics Inc. worth $3.36M as of Q1 2017.
Janus Henderson Investors US sold 27,241 Trillium Therapeutics Inc. shares in Q1 2017, an estimated $160K.
Trillium Therapeutics Inc. made up ﹤0.01% of Janus Henderson Investors US's portfolio in Q1 2017, its #857 holding.
Janus Henderson Investors US first reported a position in Trillium Therapeutics Inc. in Q2 2015 and has held it in 8 quarters since.
Janus Henderson Investors US's Trillium Therapeutics Inc. position peaked at $8.42M in Q3 2016.
22 funds tracked by Wall St. Rank held Trillium Therapeutics Inc. as of Q1 2017.

Based on Janus Henderson Investors US's 13F filing for Q1 2017, filed 16 May 2017.